Noflamen (Meloxicam)

Meloxicam, the active ingredient in Noflamen, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an oral tablet for oral use. It treats inflammation and pain associated with osteoarthritis, rheumatoid arthritis and acute musculoskeletal conditions in adults.

GNH USA supplies Noflamen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meloxicam is indicated for inflammatory joint and musculoskeletal disorders, providing pain relief and improved function.

- Osteoarthritis: reduces joint pain and improves mobility. - Rheumatoid arthritis: diminishes inflammation and slows disease‑related joint damage. - Acute musculoskeletal pain: alleviates pain and swelling after injury or overuse.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Gastrointestinal discomfort or dyspepsia. - Headache. - Dizziness. - Nausea or vomiting. - Peripheral edema. - Skin rash.

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding. - Cardiovascular events such as myocardial infarction or stroke. - Hepatic injury with elevated liver enzymes. - Renal impairment or failure. - Severe skin reactions (e.g., Stevens‑Johnson syndrome). - Anaphylaxis or other severe hypersensitivity reactions.

Before prescribing meloxicam, clinicians should evaluate patient‑specific risk factors and monitor therapy.

- Assess gastrointestinal risk: review history of ulcers, bleeding disorders, or chronic NSAID use. - Evaluate cardiovascular profile: consider existing heart disease or stroke risk. - Monitor renal function: check serum creatinine and electrolytes in patients with kidney disease. - Review hepatic status: perform liver function tests periodically. - Use caution in the elderly: lower doses may be required due to increased susceptibility to adverse effects. - Store at ambient temperature: keep below 25 °C, retain in the original packaging, and protect from moisture.

Meloxicam can alter the pharmacodynamics or pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of serious bleeding. - Other NSAIDs or COX‑2 inhibitors: additive gastrointestinal toxicity. - Lithium: meloxicam may raise lithium serum concentrations.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may reduce renal perfusion, especially in volume‑depleted patients. - Diuretics: heightened risk of renal impairment. - Selective serotonin reuptake inhibitors (SSRIs): potential for enhanced bleeding tendency.